Breath Nitric Oxide as a Predictor of Response to Anti-PD-L1 Immunotherapy in Adults with Metastatic Non-Small Cell Lung Cancer

What this Trial Is About

Researchers are studying metastatic non-small cell lung cancer NSCLC to understand how well immunotherapy works for different patients. Immunotherapy uses the bodys natural defenses to target cancer cells, but its effectiveness varies. This study aims to see if measuring the amount of nitric oxide NO in a patients breath can better predict their response to immunotherapy treatment. Participants will have breath tests to measure fractional exhaled nitric oxide FeNO before their first immunotherapy infusion and again after their fourth treatment course. The study observes patients who are newly diagnosed with metastatic NSCLC and have a high level of PD-L1 expression on their tumors. These breath tests are done alongside routine immunotherapy infusions. During the study, participants receive standard immunotherapy and have CT scans after about nine weeks, following four treatment courses, to assess their response. Researchers will compare the breath test results with these imaging outcomes to evaluate FeNO as a predictive marker. The study involves visits for breath testing before treatment and at follow-up, with monitoring continuing through treatment courses lasting approximately nine weeks.

Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer